Sotatercept safety and effects on hemoglobin, bone, and vascular calcification

Authors

Daniel W Coyne, Washington University School of Medicine in St. Louis
Hem N Singh, Celgene Corporation
William T Smith, Celgene Corporation
Ana Carolina Giuseppi, Celgene Corporation
Jamie N Connarn, Celgene Corporation
Matthew L Sherman, Acceleron Pharma Inc.
Frank Dellanna, MVZ Davita Rhein-Ruhr
Hartmut H Malluche, University of Kentucky,
Keith A Hruska, Washington University School of Medicine in St. Louis

Journal

Kidney International Reports

Publication Date

11-1-2019

Volume

4

Issue

11

First Page

1585

Last Page

1597

Document Type

Open Access Publication

DOI

10.1016/j.ekir.2019.08.001

Rights and Permissions

Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman ML, Dellanna F, Malluche HH, Hruska KA. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney Int Rep. 2019 Nov;4(11):1585-1597. doi: 10.1016/j.ekir.2019.08.001. Copyright 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Coyne, Daniel W; Singh, Hem N; Smith, William T; Giuseppi, Ana Carolina; Connarn, Jamie N; Sherman, Matthew L; Dellanna, Frank; Malluche, Hartmut H; and Hruska, Keith A, "Sotatercept safety and effects on hemoglobin, bone, and vascular calcification." Kidney International Reports. 4, 11. 1585 - 1597. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/9119